April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
7 citations
,
February 2010 in “British Journal of Dermatology” A woman with a rare autoimmune disorder had a blister on her eye and unique immune reaction, which was effectively treated with medication.
21 citations
,
December 2014 in “Clinics in dermatology” Squaric acid dibutylester effectively treats alopecia areata.
March 2026 in “Journal of the European Academy of Dermatology and Venereology” VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
1 citations
,
February 2025 in “Indian Dermatology Online Journal” Surgical treatments and topical tofacitinib may help with vitiligo-related eyebrow and eyelash whitening, but more research is needed.
June 2022 in “Zenodo (CERN European Organization for Nuclear Research)” 
2 citations
,
January 2023 in “BioMed Research International” Beetroot extract nanogel may help treat hair loss caused by testosterone.
16 citations
,
March 1996 in “PubMed” Switching to twice-weekly betamethasone led to full hair regrowth in 3 months without side effects.
November 2025 in “The Bioscan.” Pix Liquida helped a man recover from patchy hair loss.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
April 2025 in “Pharmaceutics” Oil A formulation with Baricitinib shows promise for treating alopecia areata by promoting hair growth.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
65 citations
,
April 2000 in “The Laryngoscope” Clotrimazole, miconazole, and tolnaftate are likely safe, but gentian violet is risky.
4 citations
,
June 2025 in “Frontiers in Immunology” BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
November 2025 in “Journal of Investigative Dermatology” 2 citations
,
June 2010 in “Medicina de Familia SEMERGEN” The girl's "dandruff" was actually harmless hair casts, not a hygiene issue.
August 2025 in “Biomedicines” Half-siblings with a rare skin condition improved with treatment for a fungal infection, but hair loss remained.
June 2024 in “The Journal of Dermatology” 
Melanocytes can regenerate around hair follicles in bullous pemphigoid, especially in patients with darker skin.
7 citations
,
May 1988 in “International Journal of Dermatology” The patient's hair has unique structural differences with alternating bright and dark bands.
September 2025 in “Value in Health” Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.